Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity

9 Sept 2009

Abstract excerpt

This study was designed to evaluate the expression of HER receptors as a marker of sensitivity to the humanized anti-HER2 monoclonal antibody pertuzumab in ovarian cancer cells. In a recent clinical trial, low levels of HER3 mRNA have been shown to associate with pertuzumab response when combined with gemcitabine. We sought to define how pertuzumab modulated HER expression levels in ovarian cancer using cell line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19737968
DOI: 10.1158/1541-7786.mcr-09-0101

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab SensitivityPMID 19737968Read ↗

A Central Role for HER3 in <i>HER2</i> -Amplified Breast Cancer: Implications for Targeted TherapySemantic proximity Read ↗

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signalingSemantic proximity Read ↗

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancerSemantic proximity Read ↗

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancerSemantic proximity Read ↗

Inhibition of HER Receptors Reveals Distinct Mechanisms of Compensatory Upregulation of Other HER Family Members: Basis for Acquired Resistance and for Combination TherapySemantic proximity Read ↗

High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and NeckSemantic proximity Read ↗

HER-2/neu Is Rate-limiting for Ovarian Cancer GrowthSemantic proximity Read ↗

Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell linesSemantic proximity Read ↗

Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.Semantic proximity Read ↗

Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferationSemantic proximity Read ↗

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.Semantic proximity Read ↗

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.